Clinical Trials › NCT04695080
Active, Not RecruitingPhase 2
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
Sponsored by Queen Mary University of London
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 204
Target enrollment
Jun 2021
Start date
Dec 2027
Expected completion
Interventions / Treatments
Cladribine (MAVENCLAD®)Placebo
Conditions studied
Advanced Multiple SclerosisProgressive Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.